Üks Life4me+ peamiseid eesmärke on uute HIVi- ja muude sugulisel teel levivate nakkuste juhtumite, nagu ka C-hepatiiti ja tuberkuloosi nakatumise ennetamine.

Nutirakendus aitab luua kontakti arstide ja HIV positiivsete inimeste vahel. Nutirakendus aitab mugavalt organiseerida ravimite võtmise aegu, seadistada ainult Teile arusaadavad ja personaalseid meeldetuletusi, võimaldab saada arstilt tagasisidet ning panna aega vastuvõtule või analüüsidele.

Kõik uudised / Märts 2025

Arhiiv

✕

13 märts 2025, 12:35

Dr. Alex Schneider

82

N6LS Antibody Brings Us Closer to Long-Acting HIV Treatment

N6LS Antibody Brings Us Closer to Long-Acting HIV Treatment

Scientists have been exploring long-acting treatments that require fewer doses, while still keeping HIV in check. One promising option is VH3810109 (N6LS), a special type of antibody that fights the virus in a new way.

HIVCROIART

13 märts 2025, 10:02

Dr. Alex Schneider

79

New Oral Islatravir/Doravirine Regimen Shows Strong Results in Two Phase 3 Studies

New Oral Islatravir/Doravirine Regimen Shows Strong Results in Two Phase 3 Studies

The studies, conducted by Merck & Co., Inc., suggest that switching to this new combination therapy is as effective as continuing with existing treatment regimens.

HIVCROI2025ART

13 märts 2025, 08:18

Dr. Alex Schneider

114

A Game-Changer for HIV Treatment?

A Game-Changer for HIV Treatment?

A new study conducted in Africa suggests that long-acting injectable HIV treatment could be just as effective as daily pills—and might offer a new way forward in the fight against HIV.

HIVCROI2025LA

12 märts 2025, 09:05

Dr. Alex Schneider

331

A Once-Yearly HIV Prevention Shot Could Transform PrEP Access

A Once-Yearly HIV Prevention Shot Could Transform PrEP Access

Scientists at CROI 2025 presented new research showing that a single yearly injection of lenacapavir could be just as effective as current methods — potentially revolutionizing HIV prevention.

HIVCROI2025PrEPLenacapavir

12 märts 2025, 07:46

Dr. Alex Schneider

329

A New Era in HIV Treatment: Phase 2 Study Shows Promise for Twice-Yearly Injections

A New Era in HIV Treatment: Phase 2 Study Shows Promise for Twice-Yearly Injections

For decades, people living with HIV have relied on daily oral medication to maintain viral suppression, but what if a twice-yearly injection could offer the same protection? A new Phase 2 study, presented at CROI 2025, suggests this may soon become a reality.

lenacapavirHIVCROI2025bNAbs

11 märts 2025, 16:20

Dr. Alex Schneider

367

San Francisco Rally Demands Protection for HIV Research Amid Funding Cuts

San Francisco Rally Demands Protection for HIV Research Amid Funding Cuts

Hundreds of people gathered at Yerba Buena Gardens on Monday evening for the Save Our Sciences: Rally for HIV Research, a powerful demonstration in support of life-saving HIV research programs currently at risk of losing federal funding.

HIVCROI2025

11 märts 2025, 12:34

Dr. Alex Schneider

463

RIO Study Suggests Antibodies Could Offer a Break from Daily HIV Treatment

RIO Study Suggests Antibodies Could Offer a Break from Daily HIV Treatment

The RIO study, a randomized, placebo-controlled clinical trial, found that a combination of two broadly neutralizing antibodies (bNAbs) effectively delayed viral rebound, after stopping ART, raising hopes for more flexible treatment options.

HIVCROI

11 märts 2025, 10:03

Dr. Alex Schneider

292

CROI 2025 Begins in San Francisco: Advancing Science, Strengthening Policy, and Shaping the Future of HIV Research

CROI 2025 Begins in San Francisco: Advancing Science, Strengthening Policy, and Shaping the Future of HIV Research

The Conference on Retroviruses and Opportunistic Infections (CROI) 2025 opened today in San Francisco, bringing together leading scientists, clinicians, and public health experts to discuss the latest breakthroughs and ongoing challenges in HIV and infectious disease research.

HIVCROI2025CROI